

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



NNK Group Limited
年年卡集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3773)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of NNK Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Li Yao (李耀) (“**Dr. Li**”) has been appointed as an independent non-executive Director, a member of the nomination committee of the Board (the “**Nomination Committee**”) and a member of the audit committee of the Board (the “**Audit Committee**”) with effect from 30 June 2023.

Dr. Li, aged 54, has approximately 30 years of experience in the financial industry. Dr. Li served as Chief Executive Officer of a large sized China overseas investment fund and the Chairman of its Investment Committee, and as co-Chief Executive Officer of a wholly owned investment management company for one of China’s leading insurance groups. Earlier in his career, Dr. Li worked at the head office of a top state-owned commercial bank, where he was responsible for the establishment and expansion of a multinational investment fund advisory business and a domestic investment banking business. In addition, Dr. Li received his bachelor’s degree in Finance from China Nanjing University, his master’s degree in Finance from Nankai University of China, and his doctorate degree in Economics from China Renmin University.

Dr. Li was a non-executive director of Aceso Life Science Group Limited (formerly known as Hao Tian Development Group Limited) (a company listed on the Stock Exchange, stock code: 474) between August 2020 and June 2021, and an independent non-executive director of VNET Group, Inc. (formerly known as 21Vianet Group, Inc.) (a company listed on NASDAQ, stock code: VNET) between May 2018 and August 2022. Dr. Li is currently an independent non-executive director of Bairong Inc. (a company listed on the Stock Exchange, stock code: 6608).

Save as disclosed above, Dr. Li did not hold any directorship in any listed company in Hong Kong or overseas in the last three years preceding the date of this announcement. Dr. Li also (i) does not have any relationship with any director, senior management or substantial or controlling shareholder of the Company; (ii) is not interested in or deemed to be interested in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) does not hold any other position with the Company or its subsidiaries.

Dr. Li has signed an appointment letter with the Company for a term of three years, subject to retirement by rotation and re-election at annual general meeting of the Company in accordance with the articles of association of the Company. Dr. Li is entitled to a director's fee of HK\$150,000 per annum, which was determined by the Board on the recommendation of remuneration committee with reference to his duties and responsibilities, remuneration benchmark in the industry as well as prevailing market conditions.

Dr. Li confirmed that he meets the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Save as disclosed above and as far as the Board is aware, there is no other information which is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor is there any other matter in relation to the appointment of Dr. Li that needs to be brought to the attention of the shareholders of the Company.

The Board warmly welcomes Dr. Li to join the Board.

Reference is made to the announcement of the Company dated 19 June 2023 in relation to the resignation of an independent non-executive Director of the Company (the "**Resignation**") with effect from 19 June 2023 (the "**June Announcement**"). As set out in the June Announcement, following the Resignation of the said independent non-executive Director, (i) the total number of independent non-executive Directors accounts for less than one-third of the Board members, which is below the minimum requirement set out under Rule 3.10A of the Listing Rules; (ii) the number of independent non-executive Directors and the number of members of the Audit Committee of the Company fails to meet the minimum number required under Rules 3.10(1) and 3.21 of the Listing Rules respectively; and (iii) the Nomination Committee does not comprise a majority of independent non-executive Director, therefore the Company fails to meet the requirement of Rule 3.27A of the Listing Rules. Following the appointment of Dr. Li as an independent non-executive Director, a member of the Nomination Committee and a member of the Audit Committee with effect from 30 June 2023, the Company has complied with the relevant requirements under Rule 3.10(1), Rule 3.10A, Rule 3.21 and Rule 3.27A of the Listing Rules, respectively.

By order of the Board
NNK Group Limited
Zhou Jinhuang
Director

Hong Kong, 30 June 2023

As at the date of this announcement, Mr. Huang Junmou, Dr. Zhou Jinhuang and Mr. Guan Heng are the executive Directors; Mr. Fan Weiguo and Mr. Yu Zida are the non-executive Directors; and Ms. Zou Guoying, Mr. Zhang Mingqun and Dr. Li Yao are the independent non-executive Directors.